Toward the promotion of correct regenerative medicine
The regenerative medicine law was enacted in 2013 in order to ensure that Japanese citizens can receive regenerative medicine quickly and safely. In doing so, the medical institution must submit a plan to provide regenerative medicine to a committee certified by the Minister of Health, Labor and Welfare for review.
However, in reality, there are committees that cannot be expected to conduct independent and fair reviews, and there are doubts about the scientific basis of safety and the expertise of doctors in the approved treatment plans based on the reviews by the committees. It has been reported that there are a certain number of cases that are recognized, and that inappropriate advertisements such as exaggerated advertisements may mislead patients’ understanding and treatment choices.
Some doctors in the field do not have enough knowledge, and they use it like a general medicine, and the explanation to patients is insufficient. .
Therefore, we are supporting the introduction of regenerative medicine to solve these problems.
In order for medical institutions to incorporate regenerative medicine into their medical care items, there are several hurdles, such as the selection of a cell processing manufacturer, the creation of a regenerative medicine provision plan, and the selection of equipment to be used.
Many of the supporting places where the price cheap are only for the preparation of documents, and they cannot answer the most important technical questions when providing, and there are few places that understand the quality of the cells to be provided and provide suggestions to doctors.
We not only provide documentation, but also collaborate with researchers in cell culture and regenerative medicine. In addition, we provide high quality regenerative medicine by our technical support with profound education. By increasing the number of medical institutions that properly adopt regenerative medicine, we aim to contribute to the promotion of regenerative medicine in Japan and the improvement of treatment quality, and to create world-class regenerative medicine.